In the fifth year of implementation of the special insulin collection, domestically produced insulin preparations opened the door to commercialization in the US for the first time. It is worth noting that this batch of products marketed in the US is produced from the “old face” of collection, a special drug collection production line in Yidu, Hubei. Although no domestically produced insulin product has been approved for marketing by the FDA, the model of “domestic collection, two-way supply to the European and American markets, and co-production” is no exception. According to the industry, the greater industrial significance of this overseas order is that the production quality management system of Chinese pharmaceutical companies has passed the verification of the “world's most stringent pharmaceutical market”, which directly responds to public concerns about the quality of collected drugs. As collection enters the normalized implementation stage, the “price for volume” effect in the domestic market continues to be unleashed; in addition, the internationalization of formulations has first entered the implementation period in emerging markets. Recently, in media research organized by the National Health Insurance Administration, First Finance learned that many companies that won the bid collection have returned to a growth path.

In the fifth year of implementation of the special insulin collection, domestically produced insulin preparations opened the door to commercialization in the US for the first time. It is worth noting that this batch of products marketed in the US is produced from the “old face” of collection, a special drug collection production line in Yidu, Hubei. Although no domestically produced insulin product has been approved for marketing by the FDA, the model of “domestic collection, two-way supply to the European and American markets, and co-production” is no exception. According to the industry, the greater industrial significance of this overseas order is that the production quality management system of Chinese pharmaceutical companies has passed the verification of the “world's most stringent pharmaceutical market”, which directly responds to public concerns about the quality of collected drugs. As collection enters the normalized implementation stage, the “price for volume” effect in the domestic market continues to be unleashed; in addition, the internationalization of formulations has first entered the implementation period in emerging markets. Recently, in media research organized by the National Health Insurance Administration, First Finance learned that many companies that won the bid collection have returned to a growth path.